Skip to main content

Table 1 Targeted therapies studied or under investigation in cooperation with immune therapies

From: Oncogene withdrawal engages the immune system to induce sustained cancer regression

Target protein(s) Tumor type Targeted therapy Immune therapy Refs
ALK Non-Small Cell Lung Cancer Crizotinib Ipilimumab [119]
BCR-ABL CML, GIST Imatinib, Dasatinib Interferon, Nivolumab [125]
BRAF Melanoma Vemurafenib, Dabrafenib Ipilimumab [117]
BTK Chronic Lymphocytic Leukemia Ibrutinib Lenalidomide [122]
CD20 Follicular Lymphoma Rituxamab Pidilizumab [126]
CD30 Hodgkin’s Lymphoma Brentuximab Ipilimumab [118]
EGFR Non-Small Cell Lung Cancer Erlotinib Ipilimumab, anti-PDL1 (MPDL3280A) [119, 120]
HER2/neu Breast Cancer Trastuzumab E75 peptide + GM-CSF [127]
MEK Melanoma Trametinib Ipilimumab [114, 115]
mTOR Renal Cell Cancer Temsirolimus Interferon-α [124]
PDGFR, RET, or KIT Kidney Cancer Sunitinib Nivolumab [123]
Proteosome, NF-kB Multiple Myeloma Bortezomib Lenalidomide [121]
VEGF Melanoma Aflibercept IL-2 [116]